Bladder Cancer

In this editorial note from Arjun V. Balar, MD, he discusses how the KEYNOTE-57 findings have impacted the treatment landscape for Bacillus Calmette-Guérin—refractory, high-risk nonmuscle invasive bladder cancer.

Patients with metastatic renal and urothelial bladder cancer who receive antibiotics concomitantly with immune checkpoint inhibitors have shorter progression-free survival and overall survival rates than patients who do not, according to a poster presented at the European Congress on Immunotherapies in Cancer™ conference, hosted by Physicians’ Education Resource®, LLC, September 21 and 22, 2018, in Barcelona, Spain.

CheckMate-032 investigator Jonathan E. Rosenberg, MD, discusses extended follow-up findings from the trial, as well as the future of immunotherapy in urothelial carcinoma.

Petros Grivas, MD, PhD, discusses recent immunotherapy advancements in bladder cancer and ongoing research in the field.

Arjun V. Balar, MD, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.

Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in patients with nonmuscle–invasive bladder cancer.

James L. Wade III, MD, FACP, FASCO, discusses the importance of clinical trials in the community.

Thomas Powles, MD, shares his advice for community oncologists treating patients with bladder cancer in the frontline setting. According to Powles, this is a setting where there is a lot of uncertainty that can make decision making difficult.

Padmanee Sharma, MD, PhD, discusses the development of checkpoint inhibitors in several cancers, including urothelial carcinoma, RCC, and prostate cancer. She also addresses the challenges in resistance to these agents and where some clinical trials are moving forward in the field.

According to results from an interim analysis of an ongoing single-arm open-label phase II study, pembrolizumab demonstrated promising antitumor activity in patients with high-risk nonmuscle invasive bladder cancer that are unresponsive to Bacillus Calmette-Guérin and refused or were ineligible for cystectomy.

I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.

The treatment regimen of&nbsp;nivolumab (Opdivo) at 1 mg/kg plus ipilimumab at (Yervoy) 3 mg/kg induced higher overall response rates and longer progression-free survival in patients with&nbsp;platinum-pretreated metastatic urothelial carcinoma, according to extended follow-up data reported at the 2018 ESMO Annual Congress.<br /> &nbsp;

Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.

Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to &ldquo;reflect, renew, and reignite&rdquo; in order to create a more resilient oncology team for the community.

Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored&nbsp;<em>NTRK&nbsp;</em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.

Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare &amp; Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;September 2018, including several new approvals, priority reviews, a breakthrough therapy designation, and more, in a variety of cancer types.

The FDA has received a new drug application for&nbsp;erdafitinib as a treatment for&nbsp;patients with locally advanced or metastatic urothelial carcinoma and <em>FGFR</em> genetic alterations whose tumors progressed following chemotherapy,&nbsp;Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor, has announced.

In this letter from the editor, Targeted Therapies in Oncology Editor-in-Chief, Arjun V. Balar, MD, reflects on patient advocacy and those that support patients with cancer.&nbsp;

Until recently, therapeutic options for the management of advanced urothelial cancers have been limited to traditional cytotoxic agents with modest efficacy. However, the brisk pace of recent discovery in the field of immunotherapy and molecular therapeutics has ushered in a new era for management of patients with urothelial carcinoma.